What is CAR-T cell therapy?
CAR-T cell therapy is a type of immune cell therapy used mainly in some blood cancers. This page gathers recent signals from news and studies around the world, for readers who want the general direction without marketing detail.
Did the FDA convert an accelerated approval to a full approval for CAR-T in mantle cell lymphoma?
In April 2026, the U.S. Food and Drug Administration converted an earlier accelerated approval to a full approval for a CAR-T treatment for adults with relapsed or refractory mantle cell lymphoma, after additional data from a confirmatory clinical study.
What is the overall picture of CAR-T in blood cancers?
A recent scientific review noted that several CAR-T products are approved in the United States for a number of blood-cancer indications, with thousands of active clinical trials worldwide. Challenges that remain include extending the benefit in solid tumors and simplifying manufacturing to improve access.
Is CAR-T being studied in solid tumors?
There are signs of research activity in solid tumors, including clearance to start a clinical trial of a CAR-T treatment aimed at two tumor-related targets, in adults with colorectal cancer at a later stage and in children with solid tumors who have exhausted standard options.
Has a regulator in China approved a CAR-T treatment aimed at Claudin 18.2?
A regulatory approval in China has been reported for a CAR-T treatment aimed at a solid tumor and targeting Claudin 18.2. It has been described as the first treatment of this kind for this target. This is regulatory news only, and it does not by itself show whether the treatment is suitable for a particular patient.
What was announced in October 2026 about a CAR-T study in T-cell leukemia and lymphoma?
In October 2026, it was announced that a pivotal study would expand enrollment to patients with measurable residual disease (MRD) after standard therapy, in T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL and T-LBL), to assess whether intervention is possible before a clear relapse.
Is CAR-T being studied in autoimmune disease?
Trial listings point to programs in later phases of study that explore CAR-T cell therapy outside cancer, including autoimmune disorders. These programs are still under study.
Does this replace medical advice?
These updates are general and do not replace medical advice. Readers who want to know how CAR-T cell therapy is offered within the international patient pathway at Biruni University Hospital can refer to the CAR-T cell therapy page or the contact form.
